Psychiatric Times articleshttps://www.psychiatrictimes.com/newsPsychiatric Times articles© 2026 MJH Life Sciences™ and Psychiatric Times. All rights reserved.Tue, 23 Jun 2026 21:19:56 +00005en-us14447https://www.psychiatrictimes.com/newshttps://www.psychiatrictimes.com/logo.webphttps://www.psychiatrictimes.com/view/psychiatric-pharmacogenomics-an-overviewhttps://www.psychiatrictimes.com/view/psychiatric-pharmacogenomics-an-overview<![CDATA[Learn how CYP450 genetics, phase 2 metabolism, and drug interactions shape psychiatric dosing—what’s actionable now and what’s next in PPGx.]]>Tue, 23 Jun 2026 20:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/phase-2-analysis-of-ml-004-for-autism-spectrum-disorder-fails-to-meet-endpointhttps://www.psychiatrictimes.com/view/phase-2-analysis-of-ml-004-for-autism-spectrum-disorder-fails-to-meet-endpoint<![CDATA[Phase 2 IRIS finds ML-004 misses social communication goals in autism, but notably reduces irritability in teens.]]>Tue, 23 Jun 2026 19:05:34 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/evaluating-transdermal-asenapine-in-schizophreniahttps://www.psychiatrictimes.com/view/evaluating-transdermal-asenapine-in-schizophrenia<![CDATA[Explore how the asenapine transdermal patch helps schizophrenia care with steadier dosing, fewer side effects, and new options beyond sublingual pills.]]>Tue, 23 Jun 2026 12:05:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/empowering-patients-and-expanding-formulation-options-in-schizophrenia-carehttps://www.psychiatrictimes.com/view/empowering-patients-and-expanding-formulation-options-in-schizophrenia-care<![CDATA[Clinicians empower schizophrenia patients with shared decisions and flexible treatment options—oral, long-acting injectable, or transdermal—to improve adherence, trust, and remission potential.]]>Tue, 23 Jun 2026 12:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/fda-issues-crl-for-cytisinicline-for-smoking-cessation-in-adultshttps://www.psychiatrictimes.com/view/fda-issues-crl-for-cytisinicline-for-smoking-cessation-in-adults<![CDATA[FDA issues CRL for cytisinicline, citing manufacturing issues. ]]>Mon, 22 Jun 2026 15:23:40 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/positive-topline-results-from-phase-3-emerge-study-of-dt120-odt-in-major-depressive-disorderhttps://www.psychiatrictimes.com/view/positive-topline-results-from-phase-3-emerge-study-of-dt120-odt-in-major-depressive-disorder<![CDATA[Phase 3 results show single-dose DT120 lysergide ODT delivers rapid, lasting relief in major depressive disorder with mild, transient adverse effects.]]>Mon, 22 Jun 2026 13:26:46 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/what-should-psychiatrists-know-about-pediatric-sleep-apnea-and-insomnia-treatmenthttps://www.psychiatrictimes.com/view/what-should-psychiatrists-know-about-pediatric-sleep-apnea-and-insomnia-treatment<![CDATA[Pediatric experts link insomnia and mental health, favor CBT over sedatives, and warn against cannabis for sleep.]]>Mon, 22 Jun 2026 13:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/connecting-rem-sleep-and-substance-use-vulnerabilityhttps://www.psychiatrictimes.com/view/connecting-rem-sleep-and-substance-use-vulnerability<![CDATA[Explore how circadian gene rhythms differ in schizophrenia, depression, and bipolar disorder—and why stable sleep timing may curb addiction risk.]]>Fri, 19 Jun 2026 17:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/how-can-sleep-disruption-trigger-mood-episodeshttps://www.psychiatrictimes.com/view/how-can-sleep-disruption-trigger-mood-episodes<![CDATA[Sleep and circadian rhythm disruption shape psychiatric symptoms and bipolar mood shifts.]]>Fri, 19 Jun 2026 16:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/evidence-based-nonpharmacological-interventions-in-schizophrenia-focus-on-cognitive-impairmenthttps://www.psychiatrictimes.com/view/evidence-based-nonpharmacological-interventions-in-schizophrenia-focus-on-cognitive-impairment<![CDATA[Learn how cognitive remediation, aerobic exercise, and reducing secondary risks can boost thinking skills and daily functioning in schizophrenia.]]>Fri, 19 Jun 2026 15:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/podcast-the-challenge-of-medication-adherence-with-martha-sajatovic-mdhttps://www.psychiatrictimes.com/view/podcast-the-challenge-of-medication-adherence-with-martha-sajatovic-md<![CDATA[Experts reveal why psych medication nonadherence is common, how to discuss it without blame, and tools like CAE and injectables to prevent relapse.]]>Fri, 19 Jun 2026 14:05:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/psychedelic-assisted-healing-for-system-impacted-people-a-new-research-and-policy-initiativehttps://www.psychiatrictimes.com/view/psychedelic-assisted-healing-for-system-impacted-people-a-new-research-and-policy-initiative<![CDATA[MAPS probes psychedelic-assisted healing for formerly incarcerated people, spotlighting trauma, access barriers, and a public-health policy path.]]>Thu, 18 Jun 2026 20:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/new-data-on-alixorexton-for-narcolepsy-type-2-insights-from-richard-k-bogan-mdhttps://www.psychiatrictimes.com/view/new-data-on-alixorexton-for-narcolepsy-type-2-insights-from-richard-k-bogan-md<![CDATA[Alkermes’ phase 2 Vibrance-2 shows alixorexton significantly boosts wakefulness and reduces daytime sleepiness in narcolepsy type 2, with benefits sustained.]]>Thu, 18 Jun 2026 19:23:51 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/reducing-microsleeps-oveporextons-impact-on-patient-outcomeshttps://www.psychiatrictimes.com/view/reducing-microsleeps-oveporextons-impact-on-patient-outcomes<![CDATA[New SLEEP 2026 data show orexin agonist oveporexton boosts cognition, daily function, and reduces microsleeps in narcolepsy type 1.]]>Thu, 18 Jun 2026 18:54:18 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/treating-patients-with-first-episode-psychosis-lessons-from-mclean-ontrackhttps://www.psychiatrictimes.com/view/treating-patients-with-first-episode-psychosis-lessons-from-mclean-ontrack<![CDATA[Key steps for first-episode psychosis: team-based care, low-dose meds, relapse planning, family support, and cannabis harm reduction.]]>Thu, 18 Jun 2026 14:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/alixorexton-for-the-treatment-of-narcolepsy-type-2-insights-from-sleep-2026https://www.psychiatrictimes.com/view/alixorexton-for-the-treatment-of-narcolepsy-type-2-insights-from-sleep-2026<![CDATA[Check out new phase 2 dose-ranging study data evaluating alixorexton in patients with narcolepsy type 2. ]]>Wed, 17 Jun 2026 20:20:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/individualizing-narcolepsy-care-real-world-oxybate-outcomeshttps://www.psychiatrictimes.com/view/individualizing-narcolepsy-care-real-world-oxybate-outcomes<![CDATA[REFRESH data show once-nightly sodium oxybate real-world outcomes.]]>Wed, 17 Jun 2026 17:38:18 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/real-world-outcomes-with-once-nightly-low-sodium-oxybate-in-narcolepsyhttps://www.psychiatrictimes.com/view/real-world-outcomes-with-once-nightly-low-sodium-oxybate-in-narcolepsy<![CDATA[REFRESH real-world study follows once-nightly sodium oxybate in narcolepsy.]]>Wed, 17 Jun 2026 17:03:13 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/sex-differences-sleep-problems-and-psychological-well-being-in-older-adultshttps://www.psychiatrictimes.com/view/sex-differences-sleep-problems-and-psychological-well-being-in-older-adults<![CDATA[Midlife sleep trouble predicts poorer well-being 9 years later, especially for women. Here's why clinicians should ask about sleep and menopause triggers.]]>Wed, 17 Jun 2026 15:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/the-association-between-sleep-sex-differences-and-mental-health-across-the-lifespanhttps://www.psychiatrictimes.com/view/the-association-between-sleep-sex-differences-and-mental-health-across-the-lifespan<![CDATA[Long-term study links sleep problems to poorer well-being in aging adults, highlighting sex differences and why insomnia isn’t just aging.]]>Wed, 17 Jun 2026 15:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/assessment-of-suicide-risk-in-individuals-with-schizophreniahttps://www.psychiatrictimes.com/view/assessment-of-suicide-risk-in-individuals-with-schizophrenia<![CDATA[Learn a multidimensional approach to suicide prevention in schizophrenia—screening, insight paradox, cannabis, cognition, trauma, and ethical AI monitoring.]]>Wed, 17 Jun 2026 14:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/oveporexton-improves-daily-function-cognition-and-nighttime-sleep-in-narcolepsy-type-1https://www.psychiatrictimes.com/view/oveporexton-improves-daily-function-cognition-and-nighttime-sleep-in-narcolepsy-type-1<![CDATA[New phase 3 data show oveporexton (TAK-861) boosts functioning and cognition, eases NT1 symptoms, and improves sleep]]>Wed, 17 Jun 2026 13:23:46 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/transcranial-direct-current-stimulation-to-enhance-brain-activity-applicability-for-schizophreniahttps://www.psychiatrictimes.com/view/transcranial-direct-current-stimulation-to-enhance-brain-activity-applicability-for-schizophrenia<![CDATA[New spectral sleep analysis and HD‑tDCS aim to strengthen restorative sleep and memory, offering promise for schizophrenia-related cognitive deficits.]]>Wed, 17 Jun 2026 12:18:48 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/the-switch-study-why-a-new-mechanism-demands-a-new-approachhttps://www.psychiatrictimes.com/view/the-switch-study-why-a-new-mechanism-demands-a-new-approach<![CDATA[Welcome back to another Psychiatric Times Insights series. In this episode titled, "The Switch Study: Why a New Mechanism Demands a New Approach," David Walling, PhD, address the unmet clinical needs in schizophrenia treatment that motivated the development of the study evaluating the transition from atypical antipsychotics to Cobenfy?]]>Wed, 17 Jun 2026 12:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/the-role-of-sleep-in-emotion-and-memory-processinghttps://www.psychiatrictimes.com/view/the-role-of-sleep-in-emotion-and-memory-processing<![CDATA[New SLEEP 2026 insights reveal how REM sleep preserves memories while stripping emotional sting—key clues for PTSD and healthier sleep.]]>Wed, 17 Jun 2026 01:19:23 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/my-barbaric-yawphttps://www.psychiatrictimes.com/view/my-barbaric-yawp<![CDATA["I’m a four-year-old prince with a bag of Jack Frost sand filling my sandbox kingdom..."]]>Tue, 16 Jun 2026 14:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/behavioral-sleep-medicine-approaches-for-insomnia-in-older-adultshttps://www.psychiatrictimes.com/view/behavioral-sleep-medicine-approaches-for-insomnia-in-older-adults<![CDATA[Behavioral therapies: important parts of sleep disorder treatment.]]>Tue, 16 Jun 2026 13:46:39 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/gender-differences-in-sleep-qualityhttps://www.psychiatrictimes.com/view/gender-differences-in-sleep-quality<![CDATA[Menopause-related sleep disruptions and slow-wave scoring bias may skew women’s neurodegeneration risk insights, SLEEP 2026 highlights.]]>Tue, 16 Jun 2026 13:42:40 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/choosing-the-right-formulation-in-schizophrenia-treatmenthttps://www.psychiatrictimes.com/view/choosing-the-right-formulation-in-schizophrenia-treatment<![CDATA[Clinicians weigh diagnosis clarity, side effects, and adherence when choosing antipsychotic formulations, often starting oral therapy then switching to long-acting injectables.]]>Tue, 16 Jun 2026 12:05:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/navigating-the-schizophrenia-treatment-landscape-antipsychotic-mechanisms-and-evolving-optionshttps://www.psychiatrictimes.com/view/navigating-the-schizophrenia-treatment-landscape-antipsychotic-mechanisms-and-evolving-options<![CDATA[Explore today’s schizophrenia treatments, comparing first-, second-, and newer antipsychotics, clozapine’s role, and how side effects and adherence drive medication choices.]]>Tue, 16 Jun 2026 12:00:00 GMTPsychiatric TimesusPsychiatric Times Articles